SANUWAVE Health Inc. has announced preliminary revenue results for the second quarter of 2025, indicating a range of $10.1 million to $10.2 million. This marks the highest Q2 quarterly revenues in the company's history and represents a significant increase of 41% to 42% compared to the same period in 2024. Additionally, the first half of 2025 saw revenue growth of 50-51% compared to the first half of 2024. The company attributes this revenue growth to a period of significant transition, including the addition of a new head of sales and a new head of commercial operations. SANUWAVE has rapidly expanded its sales force, reaching 13 salespeople and covering all national sales territories for the first time under CEO Morgan Frank's leadership. A key national accounts manager, dubbed the "elephant hunter," has also been added to target larger market opportunities. The company plans to release its full Q2 results on or around August 8, 2025, providing a more comprehensive update on its performance and future plans.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。